{
    "2021-03-17": [
        [
            {
                "time": "2021-04-19",
                "original_text": "Lilly (LLY) Mirikizumab Meets Ulcerative Colitis Study Goal",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Mirikizumab",
                        "Ulcerative Colitis",
                        "Study Goal"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-05-12",
                "original_text": "Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for VerzenioÂ® at St. Gallen Virtual Congress 2021",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Patient-Reported Outcomes",
                        "Phase 3",
                        "monarchE",
                        "Verzenio",
                        "St. Gallen",
                        "Virtual Congress"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-03-11",
                "original_text": "4 Pharma Stocks That Could Be Losers With the $1.9 Trillion Stimulus Package",
                "features": {
                    "keywords": [
                        "Pharma Stocks",
                        "Losers",
                        "Stimulus Package"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}